SMITHS FALLS, ON, Feb. 22, 2019 /CNW/ - Canopy Growth
Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE:
CGC) is pleased to announce the appointment of Dr. Danial Schecter as Director of Global Medical
Services. Dr. Schecter is widely recognized as an expert in the
clinical use of medical cannabis and will use his experience to
expand the Company's network of partner healthcare clinics and
support doctors and patients who understand the value of cannabis
as medicine.
"I have had the honour of serving a range of patients who, after
exhausting traditional pharmaceutical approaches, have reported the
remarkable benefits of therapeutic cannabis," said Dr. Schecter.
"As Canopy Growth's new Director of Global Medical Services, it
will be my privilege to share the lessons learned from my vast
clinical experience to benefit new cohorts of physicians and
patients, both nationally and globally, who are able to access
federally regulated medical cannabis."
Dr. Schecter's approach will rely on educational and outreach
activities, including establishing new mentorship opportunities,
developing training modules and organizing advisory boards that
will assist healthcare providers in each jurisdiction that allows
medical cannabis access. In addition, he will identify and support
clinics partnered with Spectrum Cannabis and ensure they operate at
the highest standards.
"Dr. Schecter will leverage his extraordinary wealth of
front-line clinical experience as we expand the Company's medical
cannabis practice into new jurisdictions," said Dr. Mark Ware, Chief Medical Officer, Canopy Growth.
"We look forward to working with him as we continue our efforts to
educate physicians and other healthcare providers who are committed
to ensuring patients get the access to medical cannabis they
deserve."
Prior to being appointed to his new role at Canopy Growth, Dr.
Schecter was the co-founder and Executive Director of Canabo
Medical Clinics, the largest referral-only clinic network
specializing in medical cannabis in Canada. He trained thousands of physicians and
pharmacists on how to help patients decide if cannabis was the
appropriate treatment for their specific medical conditions.
Outside of cannabinoid medicine, he holds a fellowship in Hospital
Medicine and is an active hospitalist at the Royal Victoria
Regional Health Centre in Barrie,
Ontario. Dr. Schecter is also a practicing family physician
who will continue to provide house calls to at-risk elderly and
palliative care patients.
Dr. Schecter's experience as a patient-focused family physician
and leader in the medical cannabis sector makes him a welcome
addition to Canopy Growth's team of healthcare professionals and
industry experts. Their combined efforts will further the Company's
mission to provide reliable, consistent medical cannabis products
that will improve the lives of patients around the world.
Here's to Future (medical) Growth.
About Canopy Growth Corporation
Canopy Growth is a
world-leading diversified cannabis and hemp company, offering
distinct brands and curated cannabis varieties in dried, oil and
Softgel capsule forms. Canopy Growth offers medically approved
vaporizers through the Company's subsidiary, Storz & Bickel
GMbH & Co. KG. From product and process innovation to market
execution, Canopy Growth is driven by a passion for leadership and
a commitment to building a world-class cannabis company one
product, site and country at a time. The Company has operations in
over a dozen countries across five continents.
The Company is proudly dedicated to educating healthcare
practitioners, conducting robust clinical research, and furthering
the public's understanding of cannabis, and through its wholly
owned subsidiary, Canopy Health Innovations ("Canopy Health"), has
devoted millions of dollars toward cutting edge, commercializable
research and IP development. Canopy Growth works with the Beckley
Foundation and has launched Beckley Canopy Therapeutics to research
and develop clinically validated cannabis-based medicines, with a
strong focus on intellectual property protection. Canopy Growth
acquired assets of leading hemp research company, ebbu, Inc.
("ebbu"). Intellectual Property ("IP") and R&D advancements
achieved by ebbu's team apply directly to Canopy Growth's hemp and
THC-rich cannabis genetic breeding program and its cannabis-infused
beverage capabilities. Through partly owned subsidiary Canopy
Rivers Corporation, the Company is providing resources and
investment to new market entrants and building a portfolio of
stable investments in the sector.
From our historic public listing on the Toronto Stock Exchange
and New York Stock Exchange to our continued international
expansion, pride in advancing shareholder value through leadership
is engrained in all we do at Canopy Growth. Canopy Growth has
established partnerships with leading sector names including
cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green
House seeds, Battelle, the world's largest nonprofit research and
development organization, and Fortune 500 alcohol leader
Constellation Brands, to name but a few. Canopy Growth operates ten
licensed cannabis production sites with over 4.3 million square
feet of production capacity, including over 500,000 square feet of
GMP certified production space. The Company operates Tweed retail
stores in Newfoundland and
Manitoba and has entered into
supply agreements with every Canadian province and territory. For
more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news
release contains "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995
and "forward-looking information" within the meaning of applicable
Canadian securities legislation. Often, but not always,
forward-looking statements and information can be identified by the
use of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements or information involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Canopy Growth or its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements or information contained in this news
release. Examples of such statements include statements with
respect to expand the Company's network of partner healthcare
clinics and support doctors and patients, and establishing new
mentorship opportunities, developing training modules and
organizing advisory boards. Risks, uncertainties and other factors
involved with forward-looking information could cause actual
events, results, performance, prospects and opportunities to differ
materially from those expressed or implied by such forward-looking
information, including expanding internationally and growing
patient numbers, and such risks contained in the Company's annual
information form dated June 27, 2018
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com. Although the
Company believes that the assumptions and factors used in preparing
the forward-looking information or forward-looking statements in
this news release are reasonable, undue reliance should not be
placed on such information and no assurance can be given that such
events will occur in the disclosed time frames or at all. The
forward-looking information and forward-looking statements included
in this news release are made as of the date of this news release
and the Company does not undertake an obligation to publicly update
such forward-looking information or forward-looking information to
reflect new information, subsequent events or otherwise unless
required by applicable securities laws.
SOURCE Canopy Growth Corporation